Orchid Pharma (ORCHPHARMA.NS) Stock Price

Orchid Pharma Price

CLOSED
960.40
​
Market closed

Revenue at Orchid Pharma has contracted by 0.7% per year over the past 20 years to 8.11 B INR. Earnings per share have declined at 5.0% per year over the last 20 years. Orchid Pharma's net margin stands at 2.5%, up from -0.3% several years earlier. Orchid Pharma currently offers a dividend yield of about 68.08%. Analysts set a median price target of 963.90 INR, implying 0.4% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

Orchid Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orchid Pharma business model & stock analysis

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu and currently employs 838 full-time employees. The firm is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). The company operates through the pharmaceutical segment. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

Frequently asked questions about Orchid Pharma

Analysts currently set an average price target of 981.24 INR for the Orchid Pharma stock (median: 963.90 INR), implying +2.2 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Orchid Pharma stock: 8 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Orchid Pharma share trades at 9.43 EUR (960.40 INR).

The revenue of Orchid Pharma is 8.11 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Orchid Pharma is 205.47 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Orchid Pharma is currently 237.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orchid Pharma stock.

The price-to-sales ratio (P/S) of Orchid Pharma is currently 6.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orchid Pharma stock.

The Eulerpool Quality Score for Orchid Pharma is 3/10.

The ISIN of Orchid Pharma is INE191A01027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Orchid Pharma is ORCHPHARMA.NS. The ticker symbol is used to trade Orchid Pharma shares on the stock exchange.

Fair ValueTerminal
816.34 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
9.68 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Sep 6, 1993
ISIN
INE191A01027
Cusip
Y6S9KA106
Market capitalization
48.71 B INRLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
120.05
P/Ee 2028
—
P/S
P/Se
3.78
EV/EBIT
920.91
P/B Ratio
3.78
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.24 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
68.08 %
Payout Ratio
3,613.89 %
Dividend growth Ø5Y
24.57 %
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Nov 22, 2026, 3:42 AM

Orchid Pharma Peer Group

Orchid Pharma FIGI

ORCP:IN · BBG000CX7ZK6ORCP:IB · BBG000CX8059ORCP:IS · BBG000CX80T3ORCP:IG · BBG003NVXCS6

All fundamentals and in-depth analysis of Orchid Pharma

Our stock analysis for Orchid Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchid Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.